Navigation Links
FluoroPharma Medical Announces Stock Ticker Symbol Change
Date:6/3/2011

BOSTON, June 3, 2011 /PRNewswire/ -- FluoroPharma Medical (OTC.BB: FPMI), a biopharmaceutical company developing the next generation proprietary PET imaging products, announced the change of its official stock ticker symbol from CEWM to FPMI.  These changes are made in conjunction with the previously announced FluoroPharma Inc. merger with CEWM.

About FluoroPharma

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. FluoroPharma is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target myocardial cells within the heart or inflamed plaques within the coronary arteries.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE FluoroPharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Physicians Growing Demand for Point-of-Care Resources Spawns iPointOfCare From Top Continuing Medical Education Provider; DIME
2. Pennington Biomedical Research Center Study Suggests Decreases in U. S. Occupation Energy Levels a Significant Trigger of Obesity Epidemic
3. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
4. BioDrain Medical, Inc. Granted Canadian Patent for its Streamway® Surgical Fluid Management System
5. International Medical Group Again Among the ICIC and Fortune Magazines Inner City 100 Winners
6. OVA1 Blood Test Detects Ovarian Cancer More Accurately Than Medically Accepted CA 125 Method for Evaluating Women with Ovarian Mass
7. OncoSec Medical Featured in Medical Device Daily
8. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
9. Saladax Biomedical, Inc. Announces European Commercialization Team
10. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
11. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company ... National Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month ... technology and is expected to deliver therapeutic levels of olanzapine for a period of ...
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... (NASDAQ: VWR), the leading global independent provider of product and ... financial results for the fourth quarter and full year ended ... 4Q16 record quarterly net sales of $1.13 billion, up 1.6% ... 4Q16 EMEA-APAC segment net sales increased 0.4%, ... sales increased 2.5%, or down 0.9% on an organic basis, ...
Breaking Biology Technology:
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):